Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Current Medical Research and Opinion

Volumn 30, Issue 6, 2014, Pages 1007-1016

  André, Fabrice ^a   Neven, Patrick ^b   Marinsek, Nina ^c   Zhang, Jie ^d   Baladi, Jean Francois ^d   Degun, Ravi ^c   Benelli, Giancarlo ^e   Saletan, Stephen ^d   Jerusalem, Guy ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Navigant Consulting Inc   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Farma SpA   (Italy)

^f UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Advanced breast cancer; Chemotherapy; Endocrine hormone therapy; Europe; Guideline

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; DISEASE SEVERITY; EUROPE; EVALUATION STUDY; FAMILY HISTORY; FEMALE; GENERAL HOSPITAL; GYNECOLOGIST; HEALTH CARE UTILIZATION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; PHYSICIAN; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIVATE PRACTICE; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT RESPONSE; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DEFICIENCY; METABOLISM; MIDDLE AGED;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84900832306     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.887002     Document Type: Article

References (19)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 1.2013. Available at: www.nccn.com [Last accessed 4 December 2013]
2. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
3. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
4. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007;25:191-5
5. DeKoven M, Bonthapally V, Jiao X, et al. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 2012;1:453-63
6. Jackisch C, Untch M, Chatsiproios D, et al. Adherence to treatment guidelines in breast cancer care-A retrospective analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'. Breast Care (Basel) 2008;3:87-92
7. Wu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012;30:142-50
8. Wockel A, Varga D, Atassi Z, et al. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie 2010;33:21-8
9. Wolters R, Wockel A, Wischnewsky M, et al. [Effects of guideline-compliant therapy on the survival of patients with primary breast cancer: results of a retrospective cohort study]. Z Evid Fortbild Qual Gesundhwes 2011;105:468-75
10. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010;28:1958-62
11. Jerusalem G, Marinsek N, Ricci J-F, et al. Clinical management and resource utilisation for hormone-receptor-positive HER2-negative (HR+ HER2~) advanced breast cancer (BC) in Europe. Abstract 336P. Poster presented at: 2012 ESMO Congress, 28 September-2 October 2012, Vienna, Austria
12. Saad ED. Endpoints in advanced breast cancer: methodological aspects & clinical implications. Indian J Med Res 2011;134:413-18
13. Verma S, McLeod D, Batist G, et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011;16:25-35
14. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9
15. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
16. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009;117:69-75
17. Bouaud J, Messai N, Laouenan C, et al. Elicitating patient patterns of physician non-compliance with breast cancer guidelines using formal concept analysis. Stud Health Technol Inform 2012;180:477-81
18. Seroussi B, SouletA, Messai N, etal. Patient clinical profiles associated with physician non-compliance despite the use of a guideline-based decision support system: a case study with OncoDoc2 using data mining techniques. AMIA Annu Symp Proc 2012;2012:828-37
19. Fleeman N, BagustA, Boland A, etal. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess 2011;15:1-93, iii-iv